{"id":405632,"date":"2019-08-10T00:00:00","date_gmt":"2019-08-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0032-2018-biopharma-multiple-sclerosis-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-03-31T10:46:30","modified_gmt":"2026-03-31T10:46:30","slug":"algocg0032-2018-biopharma-multiple-sclerosis-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0032-2018-biopharma-multiple-sclerosis-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Multiple Sclerosis | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p>With more than a dozen disease-modifying therapies (<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s) available to treat multiple sclerosis (<abbr title=\"multiple sclerosis\">MS<\/abbr>), the treatment journey for <abbr title=\"multiple sclerosis\">MS<\/abbr> patients is varied and complex. To date, the <abbr title=\"multiple sclerosis\">MS<\/abbr> market has accommodated a place for each therapy due to the disease\u2019s heterogeneity, individualized treatment decisions, and a mix of positive and negative attributes that define each <abbr title=\"disease-modifying therapy\">DMT<\/abbr>. With every new launch, players in the <abbr title=\"multiple sclerosis\">MS<\/abbr> space\u2014both new and old\u2014must assess where their products fit into the increasingly crowded market that will be increasingly affected by the presence of generics. Meanwhile, competing paradigms of escalation versus early intervention with high-efficacy drugs remain a source of debate. As such, patients\u2019 journey through lines of therapy will continue to evolve. National patient-level claims data explore current <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s\u2019 position in newly diagnosed and recently treated patients and examine the line-of-therapy progression, including treatment duration and switch patterns and persistence and compliance by brand.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul>\n<li>What patient share do key brands garner by line of therapy in newly diagnosed <abbr title=\"multiple sclerosis\">MS<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"multiple sclerosis\">MS<\/abbr> patients?<\/li>\n<li>How have newer entrants been integrated into the treatment algorithm?<\/li>\n<li>What proportion of <abbr title=\"multiple sclerosis\">MS<\/abbr> patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with <abbr title=\"multiple sclerosis\">MS<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand\u2019s share.<\/p>\n","protected":false},"template":"","class_list":["post-405632","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/405632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/405632\/revisions"}],"predecessor-version":[{"id":405930,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/405632\/revisions\/405930"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=405632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}